Balaji Prasad
Stock Analyst at Barclays
(3.12)
# 1,229
Out of 4,722 analysts
141
Total ratings
45.3%
Success rate
0.36%
Average return
Main Sectors:
Stocks Rated by Balaji Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVNC Revance Therapeutics | Maintains: Equal-Weight | $7 → $3 | $3.39 | -11.50% | 9 | Dec 23, 2024 | |
| TEVA Teva Pharmaceutical | Maintains: Overweight | $25 → $28 | $21.49 | +30.29% | 11 | Dec 18, 2024 | |
| LGND Ligand Pharmaceuticals | Maintains: Overweight | $150 → $160 | $110.58 | +44.69% | 15 | Dec 16, 2024 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $13 → $20 | $21.48 | -6.89% | 7 | Nov 12, 2024 | |
| PCRX Pacira BioSciences | Maintains: Equal-Weight | $25 → $17 | $18.58 | -8.50% | 7 | Nov 12, 2024 | |
| VTRS Viatris | Maintains: Underweight | $11 → $12 | $11.96 | +0.33% | 7 | Nov 8, 2024 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $19 → $20 | $11.55 | +73.16% | 12 | Nov 8, 2024 | |
| RDY Dr. Reddy's Laboratories | Maintains: Overweight | $17 → $17 | $15.81 | +7.53% | 13 | Nov 6, 2024 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $570 → $481 | $432.36 | +11.25% | 8 | Nov 4, 2024 | |
| EOLS Evolus | Maintains: Overweight | $20 → $16 | $10.21 | +56.71% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $10 | $8.06 | +24.07% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $230 → $242 | $165.02 | +46.65% | 15 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $18 | $13.25 | +35.85% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $60 | $55.24 | +8.62% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $230 → $200 | $120.23 | +66.35% | 9 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $10 | $2.99 | +234.45% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $1.51 | +363.58% | 7 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $16.00 | +75.00% | 1 | Sep 21, 2023 |
Revance Therapeutics
Dec 23, 2024
Maintains: Equal-Weight
Price Target: $7 → $3
Current: $3.39
Upside: -11.50%
Teva Pharmaceutical
Dec 18, 2024
Maintains: Overweight
Price Target: $25 → $28
Current: $21.49
Upside: +30.29%
Ligand Pharmaceuticals
Dec 16, 2024
Maintains: Overweight
Price Target: $150 → $160
Current: $110.58
Upside: +44.69%
Phibro Animal Health
Nov 12, 2024
Maintains: Underweight
Price Target: $13 → $20
Current: $21.48
Upside: -6.89%
Pacira BioSciences
Nov 12, 2024
Maintains: Equal-Weight
Price Target: $25 → $17
Current: $18.58
Upside: -8.50%
Viatris
Nov 8, 2024
Maintains: Underweight
Price Target: $11 → $12
Current: $11.96
Upside: +0.33%
Elanco Animal Health
Nov 8, 2024
Maintains: Overweight
Price Target: $19 → $20
Current: $11.55
Upside: +73.16%
Dr. Reddy's Laboratories
Nov 6, 2024
Maintains: Overweight
Price Target: $17 → $17
Current: $15.81
Upside: +7.53%
IDEXX Laboratories
Nov 4, 2024
Maintains: Overweight
Price Target: $570 → $481
Current: $432.36
Upside: +11.25%
Evolus
Sep 13, 2024
Maintains: Overweight
Price Target: $20 → $16
Current: $10.21
Upside: +56.71%
Aug 13, 2024
Maintains: Overweight
Price Target: $8 → $10
Current: $8.06
Upside: +24.07%
Aug 7, 2024
Maintains: Overweight
Price Target: $230 → $242
Current: $165.02
Upside: +46.65%
Jul 25, 2024
Maintains: Overweight
Price Target: $22 → $18
Current: $13.25
Upside: +35.85%
May 10, 2024
Maintains: Overweight
Price Target: $50 → $60
Current: $55.24
Upside: +8.62%
May 3, 2024
Maintains: Overweight
Price Target: $230 → $200
Current: $120.23
Upside: +66.35%
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $2.99
Upside: +234.45%
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $1.51
Upside: +363.58%
Sep 21, 2023
Initiates: Overweight
Price Target: $28
Current: $16.00
Upside: +75.00%